- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04347798
IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT (IMPACT)
IMPact of Inflammatory Arthritis on COVID-19 sTudy of the RAPPORT-ONTRAAC and FORCAST Rheumatic Disease Registries
Study Overview
Status
Intervention / Treatment
Detailed Description
PURPOSE:
- To evaluate the impact of anti-malarial medications (hydroxychloroquine and chloroquine) on the development and severity of COVID-19 infection during the current COVID-19 pandemic in an inception cohort registry of northern Alberta rheumatoid and psoriatic arthritis patients who are on complex biologic therapies for the duration of the pandemic.
- To further evaluate the impact of all biologic medications currently in the registry on the development and severity of COVID-19 by mechanism of action (eg. TNF antagonism vs IL-6 blockade, etc).
HYPOTHESIS: We hypothesize that the "case" group of patients on concomitant anti-malarial treatment with their biologic agent will have a lower incidence and severity of COVID-19 infection compared to those not on anti-malarials based on anecdotal reports of efficacy of anti-malarials on COVID-19 infection from international reports.
JUSTIFICATION: The COVID-19 pandemic has introduced unforeseen challenges internationally and led to great uncertainty for patients who are immunocompromised, such as patients in the RAPPORT registry. Recent anecdotal reports from other countries have been associated with media and political escalation of the potential benefit of anti-malarial drugs on the course of COVID-19 infection. This has led to threats to the supply of anti-malarials drugs for patients with rheumatic diseases like lupus and rheumatoid and psoriatic arthritis, where the benefits are proven. The RAPPORT inception cohort registry provides a unique opportunity to evaluate the impact of COVID-19 in an immunocompromised population, while also evaluating the potential impact of possible treatments for COVID-19.
OBJECTIVES:
Primary
- To evaluate the impact of anti-malarial medications (hydroxychloroquine and chloroquine) on the development and severity of COVID-19 infection during the current COVID-19 pandemic in an inception cohort registry of northern Alberta rheumatoid and psoriatic arthritis patients who are on complex biologic therapies for the duration of the pandemic.
- To further evaluate the impact of all biologic medications currently in the registry on the development and severity of COVID-19 by mechanism of action (eg. TNF antagonism vs IL-6 blockade, etc).
Secondary
- To evaluate the incidence of COVID-19 versus other infections over the remaining duration of the pandemic in an immunocompromised population.
- To compare the incidence of COVID-19 versus other infections over the remaining duration of the pandemic in the proportion of patients from the RAPPORT registry who take concomitant anti-malarials versus those patients that do NOT take anti-malarials.
- To compare the impact of different mechanisms of action of biologic medications within the RAPPORT registry, on the incidence of COVID-19 versus other infections
RESEARCH METHOD/PROCEDURES:
For this case control study, we have identified ~900 patients within the RAPPORT-ONTRAAC registry who are taking concomitant anti-malarial medications with their biologic medication compared to ~ 1500 patients who are NOT taking concomitant anti-malarial medications. The current consent for the RAPPORT-ONTRAAC registry allows patients to be contacted for their potential participation in future studies. Based on this consent, we aim to send a letter to all existing RAPPORT patients inviting them to participate in this study.
This letter will be sent by email to those with an associated email address and by Canada Post mail for those who do not. Similar to previous surveys we have conducted, the letter will provide a synopsis of the current situation with the COVID-19 pandemic and request for the patient to consent to the following: (1) consent to receive email/letters with surveys of their clinical status at week 0 (the first point of contact), week 2, then every 4 weeks until the pandemic is over according to the World Health Organization or most appropriate local declaration and (2) consent to allow the study team access to the patient's medical health records (Connectcare/Netcare) for the duration of the pandemic to provide complete information regarding any healthcare utilization, investigations and outcomes over time. The act of consent will be obtained if the patient answers specifically that the study team can access their records and by the act of completing the survey every time. We will collect a blood sample when the pandemic is over from the consenting patients for consideration of serology testing.
The survey will screen for clinical symptoms of COVID-19 and concomitant status of their inflammatory arthritis and medication use. This information is linked by a unique identifier with the RAPPORT-ONTRAAC registry. The RAPPORT-ONTRAAC registry collects baseline, and at least annual information including patient demographics, ethnicity, disease characteristics, serologies, and patient-reported outcomes evaluating the impact of arthritis on their activities of daily living. With the additional linkage to their electronic medical records, we aim to identify the following: hospitalizations, and laboratory and diagnostic investigations. Access to the entire cohort's electronic medical records will provide the opportunity to capture patients who may not develop any symptoms consistent with COVID and/or may not be keen to participate in ongoing surveys but may be impacted by COVID-19. The subset of patients who develop COVID-19 will be contacted to participate in the associated study (Persistence of SARS-CoV2 in immunocompromised patients; Dr. M. Osman) for more in-depth serological evaluations and nasopharyngeal swabs. At the end of the study, we will collect a blood sample as well to ensure that COVID-19 serological evaluations are completed on asymptomatic individuals who participated in the study.
The survey, developed in collaboration with Infectious Disease experts (Drs. Sonpar, Swartz, Shafran, Singh), will screen for currently recognized signs and symptoms of COVID-19. Additionally, confirmation of current arthritis medication use including all disease modifying anti-rheumatic drugs (DMARDS) as well as biologics will be captured. Surveys will be completed on REDCAP through email link, provided directly on the email or as a hyperlink that the patient can type in if they receive the survey by Canada Post. The REDCAP survey will be developed and housed by EPICORE (Epidemiology and Research Coordinating Center).
For the remainder of the pandemic, electronic medical record and NETCARE searches will be conducted for all consenting patients with pre-specified outcomes and interim investigations and/or procedures or hospitalizations in Alberta Health Services facilities. REDCAP survey responses will be collated with these searches.
PLAN FOR DATA ANALYSIS: A response rate of 40% is expected for this study. Descriptive data analyses will be conducted to describe the population of inflammatory arthritis patients divided between those who are currently taking an anti-malarial and those who are not. The registry provides information including demographics (gender, age, ethnicity) and at least annual disease activity status with validated disease activity scores which differentiate between low disease activity state/remission and mild, moderate and severe disease activity. Co-morbidities through the Charlson Comorbidity Index will be identified and compared between groups. Survey results over the pandemic per patient will be analyzed. Electronic medical records will be reviewed at least monthly for all consenting patients to identify and quantify investigations, procedures and healthcare resources utilized during the pandemic.
With multivariate analyses, the impact of anti-malarial use on the development and severity of COVID-19 will be evaluated between the two groups, adjusting for important confounders including the following: co-morbidities (eg. cardiac and respiratory diseases, diabetes), biologic mediations, steroid use and other DMARDs. Further stratification by biologic DMARD might be conducted. Healthcare utilization between groups will be compared over time. Quantification of antibodies to Covid-19 will be compared between the anti-malarial and non-anti-malarial groups.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2G3
- University of Alberta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Current active and consented patient of the Rheumatoid Arthritis Pharmacovigilance Program of Northern Alberta with an e-mail or mailing address
Exclusion Criteria:
- Unable to read English; not consenting to be contacted for future studies
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Inflammatory arthritis patients on biologic + anti-malarial
Patients in northern Alberta receiving hydroxychloroquine or chloroquine +/- other disease modifying anti-rheumatic drug + biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker)
|
Prospective evaluation of development of Covid-19 in inflammatory arthritis patients on biologics with anti-malarials compared to inflammatory arthritis patients on biologics without anti-malarial exposure
|
Inflammatory arthritis patients on biologic + NO anti-malarial
Patients in northern Alberta receiving a biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker) +/- any disease modifying anti-rheumatic drug except for anti-malarials (hydroxychloroquine or chloroquine)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group
Time Frame: 12 months
|
Number of patients developing signs and symptoms of Covid-19 or other infections
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group
Time Frame: 12 months
|
Number of patients developing Covid-19 infection
|
12 months
|
Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action
Time Frame: 12 months
|
Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantification of Covid-19 antibodies in anti-malarial vs non-anti-malarial groups of inflammatory arthritis patients
Time Frame: 6 months
|
Quantitative measurement of Covid-19 serology to understand possible differences in degree of immune response adjusted for anti-malarial and/or biologic exposure
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephanie O Keeling, MD, University of Alberta
- Principal Investigator: Walter P Maksymowych, MD, University of Alberta
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Autoimmune Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Skin Diseases, Papulosquamous
- Spinal Diseases
- Bone Diseases
- Spondylarthropathies
- Spondylarthritis
- Spondylitis
- Psoriasis
- COVID-19
- Arthritis
- Arthritis, Rheumatoid
- Infections
- Arthritis, Psoriatic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Amebicides
- Chloroquine
- Hydroxychloroquine
Other Study ID Numbers
- Pro00100000
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on Hydroxychloroquine/Chloroquine
-
University of OxfordCompletedCoronavirus | COVID19 | Acute Respiratory IllnessesUnited Kingdom, Zambia, Thailand, Benin, Côte D'Ivoire, Indonesia, Kenya, Mali, Nepal, Pakistan
-
University of Cape TownWithdrawn
-
Tanta UniversityCompleted
-
Tanta UniversityCompletedCOVID-19 | Coronavirus InfectionEgypt
-
Washington University School of MedicineTerminatedCoronavirus InfectionUnited States
-
Government of Punjab, Specialized Healthcare and...Services Hospital, Lahore; Mayo Hospital Lahore; Pakistan Kidney and Liver InstituteTerminatedCovid-19 | Sars-CoV2 | Symptomatic ConditionPakistan
-
Government of Punjab, Specialized Healthcare and...Harvard School of Public Health (HSPH); Forman Christian College, Pakistan; Services... and other collaboratorsTerminatedCOVID-19 | Coronavirus Infection | SARS-CoV-2 | Asymptomatic ConditionPakistan
-
Henan Cancer HospitalNot yet recruitingHydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung CancerLung Neoplasms | Gemcitabine | Hydroxychloroquine
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Autoimmunity Centers of ExcellenceTerminatedSystemic Lupus Erythematosus | SLEUnited States
-
UMC UtrechtZonMw: The Netherlands Organisation for Health Research and DevelopmentTerminated